OBJECTIVE: Metastatic breast cancer in internal mammary (IM) lymph nodes is associated with a poor prognosis. This study correlates (18)F-FDG PET/CT-positive IM lymph nodes with ultrasound-guided fine-needle aspiration (FNA) cytopathologic results and determines risk factors for IM node positivity on PET/CT. MATERIALS AND METHODS: For this retrospective study, a database search was performed to identify patients referred for whole-body (18)F-FDG PET/CT for initial staging or restaging of breast cancer from January 1, 2005, through December 31, 2010. The radiology reports and images were reviewed for patients with (18)F-FDG-avid IM lymph nodes on PET/ CT and correlated with the cytopathologic results from FNA of selected PET/CT-positive IM lymph nodes. The patients with positive IM nodes on PET/CT who underwent PET/CT for initial staging were compared against age-matched and tumor size-matched patients to identify risk factors for IM node positivity on PET/CT. RESULTS: One hundred ten of 1259 patients (9%) had an (18)F-FDG-avid IM lymph node on PET/CT. Twenty-five patients underwent ultrasound-guided FNA of a suspicious IM node, and 20 IM lymph nodes (80%) were cytologically proven metastases from the primary breast malignancy. High tumor grade, the presence of lymphovascular invasion (LVI), and triple receptor-negative hormonal receptor status were found to be significant risk factors for IM node positivity on PET/CT (p < 0.05). CONCLUSION: Although fewer than 10% of breast cancer patients have positive IM nodes on (18)F-FDG PET/CT performed for initial staging or restaging, a positive IM node indicates a very high likelihood of malignant involvement on ultrasound-guided FNA. The presences of high tumor grade, LVI, or triple receptor-negative status are risk factors for IM node positivity on (18)F-FDG PET/CT.
OBJECTIVE: Metastatic breast cancer in internal mammary (IM) lymph nodes is associated with a poor prognosis. This study correlates (18)F-FDG PET/CT-positive IM lymph nodes with ultrasound-guided fine-needle aspiration (FNA) cytopathologic results and determines risk factors for IM node positivity on PET/CT. MATERIALS AND METHODS: For this retrospective study, a database search was performed to identify patients referred for whole-body (18)F-FDG PET/CT for initial staging or restaging of breast cancer from January 1, 2005, through December 31, 2010. The radiology reports and images were reviewed for patients with (18)F-FDG-avid IM lymph nodes on PET/ CT and correlated with the cytopathologic results from FNA of selected PET/CT-positive IM lymph nodes. The patients with positive IM nodes on PET/CT who underwent PET/CT for initial staging were compared against age-matched and tumor size-matched patients to identify risk factors for IM node positivity on PET/CT. RESULTS: One hundred ten of 1259 patients (9%) had an (18)F-FDG-avid IM lymph node on PET/CT. Twenty-five patients underwent ultrasound-guided FNA of a suspicious IM node, and 20 IM lymph nodes (80%) were cytologically proven metastases from the primary breast malignancy. High tumor grade, the presence of lymphovascular invasion (LVI), and triple receptor-negative hormonal receptor status were found to be significant risk factors for IM node positivity on PET/CT (p < 0.05). CONCLUSION: Although fewer than 10% of breast cancerpatients have positive IM nodes on (18)F-FDG PET/CT performed for initial staging or restaging, a positive IM node indicates a very high likelihood of malignant involvement on ultrasound-guided FNA. The presences of high tumor grade, LVI, or triple receptor-negative status are risk factors for IM node positivity on (18)F-FDG PET/CT.
Authors: Maxine S Jochelson; Lizza Lebron; Stefanie S Jacobs; Junting Zheng; Chaya S Moskowitz; Simon N Powell; Virgilio Sacchini; Gary A Ulaner; Elizabeth A Morris; D David Dershaw Journal: AJR Am J Roentgenol Date: 2015-10 Impact factor: 3.959
Authors: Min Jung Seo; Jong Jin Lee; Hye Ok Kim; Sun-Young Chae; Seol Hoon Park; Jin-Sook Ryu; Sei Hyun Ahn; Jong Won Lee; Byung Ho Son; Gyung-Yub Gong; Dae Hyuk Moon Journal: Eur J Nucl Med Mol Imaging Date: 2013-11-06 Impact factor: 9.236
Authors: Kyubo Kim; Yuri Jeong; Kyung Hwan Shin; Jin Ho Kim; Seung Do Ahn; Su Ssan Kim; Chang-Ok Suh; Yong Bae Kim; Doo Ho Choi; Won Park; Jihye Cha; Mison Chun; Dong Soo Lee; Sun Young Lee; Jin Hee Kim; Hae Jin Park; Wonguen Jung Journal: Cancer Res Treat Date: 2019-03-15 Impact factor: 4.679
Authors: Janna Morawitz; Nils-Martin Bruckmann; Frederic Dietzel; Tim Ullrich; Ann-Kathrin Bittner; Oliver Hoffmann; Eugen Ruckhäberle; Svjetlana Mohrmann; Lena Häberle; Marc Ingenwerth; Daniel Benjamin Abrar; Lino Morris Sawicki; Katharina Breuckmann; Wolfgang Peter Fendler; Ken Herrmann; Christian Buchbender; Gerald Antoch; Lale Umutlu; Julian Kirchner Journal: Eur J Nucl Med Mol Imaging Date: 2021-09-03 Impact factor: 9.236